



7th August 2025

To,
BSE Limited
P J Towers, Dalal Street,
Fort, Mumbai- 400 001.

To,
National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra(E), Mumbai- 400 051.

Scrip Code : 524518

Scrip Code : KREBSBIO

Dear Sir / Madam,

Sub: Outcome of Board Meeting - Unaudited Financial Results for the 1st quarter ended 30th June 2025.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today approved and taken on record the following:

1. Unaudited Financial Results of the Company for the 1st quarter ended 30th June 2025.
2. Limited Review Report by the Auditors on the Unaudited Financial Results for the quarter ended 30th June 2025.
3. Appointment of Mr. Manish Kumar Jain (DIN: 06477976) as an Additional Director of the Company w.e.f. 7th August 2025.
4. Appointment of Mr. Manish Kumar Jain (DIN: 06477976) as Managing Director & CEO of the Company w.e.f. 7th August 2025 subject to approval of shareholders at 33rd Annual General Meeting.
5. Resignation of Mr. Jitendra Shah (DIN: 09377846) as Managing Director/ CEO as well as Director of the Company w.e.f. 7th August 2025.
6. The Board has also reconstituted the following committees of the Board w.e.f. 8th August 2025. The revised Board Committees will now comprise of the following Board Members:

Audit Committee	
Mr. P M Kathariya	Chairman of the Committee/Independent Director
Ms. Dipti Shah	Independent Director
Mr. Satya Prakash Chigurupati	Independent Director
Mr. Sumanth Karlapudi	Independent Director
Mr. Manish Kumar Jain	Managing Director & CEO

Stakeholder Relationship Committee	
Mr. Sumanth Karlapudi	Chairman of the Committee/Independent Director
Ms. Dipti Shah	Independent Director
Mr. Satya Prakash Chigurupati	Independent Director
Mr. P M Kathariya	Independent Director
Mr. Manish Kumar Jain	Managing Director & CEO



The requisite details as per Regulation 30 of the SEBI LODR is enclosed as Annexure I.

The Meeting of the Board of Directors commenced at 12:00 noon and concluded at 02:05p.m.

The above is for your information and record.

Thanking you,



Yours Faithfully,

For **Krebs Biochemicals and Industries Limited**

Rakesh R Kalbate

Company Secretary & Compliance Officer

Encl.: a/a.

KREBS BIOCHEMICALS & INDUSTRIES LIMITED					
CIN:L24110AP1991PLC103912					
Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031.					
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025					
(Rs. In lacs)					
Sl.No	Particulars	Quarter Ended			Year Ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(Un Audited)	(Audited) *	(Un Audited)	(Audited)
1	Revenue from Operations	548.09	610.05	1,288.90	4,331.19
2	Other Income	1.17	33.80	3.35	70.89
3	Total Income (1+2)	549.26	643.85	1,292.25	4,402.08
4	Expenses				
	a) Cost of Material Consumed	3.93	(9.93)	37.29	249.29
	b)Purchase of Stock-in-Trade	-	-	3.65	3.67
	c) Changes in Inventories of Finished goods, Work-In-Progress	24.99	66.63	84.82	302.61
	d) Employee Benefits Expenses	275.11	345.40	424.90	1,659.84
	e) Finance Costs	165.01	161.47	131.81	591.42
	f) Depreciation and Amortisation Expense	159.87	156.90	169.05	668.92
	g) Other Expenses	452.78	748.71	957.85	3,618.75
	Total Expenses (4)	1,081.69	1,469.16	1,809.36	7,094.48
5	Profit / (Loss) before exceptional items and tax (3-4)	(532.43)	(825.31)	(517.11)	(2,692.40)
6	Exceptional Items:	-	-	-	-
7	Profit / (Loss) before Tax (5+6)	(532.43)	(825.31)	(517.11)	(2,692.40)
8	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Tax Payment of earlier years	-	1.53	-	1.53
	c) Deferred Tax	-	-	-	-
9	Profit / (Loss) for the period from Continuing Operations (7 + 8)	(532.43)	(826.84)	(517.11)	(2,693.93)
10	Other Comprehensive Income (OCI)				
i	Items that will not be reclassified to profit or Loss	-	(8.29)	-	(8.29)
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-
iii	Items that will be reclassified to profit or Loss	-	-	-	-
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-
	Other Comprehensive Income (Net of Tax)	-	(8.29)	-	(8.29)
11	Total Comprehensive Income for the period(9+10)	(532.43)	(835.13)	(517.11)	(2,702.22)
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	2,156.06	2,156.06
13	Other Equity	-	-	-	(17,885.02)
14	Earning Per Share (of Rs.10/- each) (not Annualised)				
	a) Basic	(2.47)	(3.83)	(2.40)	(12.49)
	b) Diluted	(2.47)	(3.83)	(2.40)	(12.49)
15	Net Worth (including Retained Earnings)	-	-	-	(14,623.88)
Notes:					
1	The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on Aug 07, 2025.				
2	The Statutory Auditors have carried out audit of the aforesaid results and have issued their "Unmodified Report" thereon.				
3	The above financial results are prepared in accordance with the Indian Accounting Standards(IND AS) as prescribed under Section 133 of the companies Act,2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations,2015 (as Amended).				
4	* The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year 2024-25 and the published year to date reviewed figures Upto December 31, 2024.				
5	The Company is operating in one segment only hence no segment results have been disclosed.				
6	The operations of the Company in Vizag manufacturing unit is closed pursuant to an order dated 07th February 2025 passed by Andhra Pradesh Pollution Control Board.				
7	As at June 30,2025 the Company does not have any Subsidiary/Associate/Joint venture company(ies).				
8	Figures of the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary.				
Place: Mumbai				 Jitendra Shah Managing Director DIN : 09377846	
Date: 07.08.2025					



Independent Auditor's Review Report on the Quarterly Unaudited standalone Financial Results of the company pursuant to the regulation 33 and 52 of the SEBI(Listing Obligation and Disclosure Requirements)Regulation,2015, as amended

Review Report to

The Board of Directors,

M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED

- a) We have reviewed the accompanying statement of unaudited standalone financial results of M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED ("the company") for the quarter ended 30th June, 2025 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended(the "Listing Regulations")
- b) The statement, which is the responsibility of the Company's Management and approved by the Board of Directors ,has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('IND AS') specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : Hyderabad
Date : 07-08-2025

For Bhavani & Co.

Chartered Accountants

Firm Registration No: 012139S

CA S Kavitha Padmini

Partner

Membership no: 229966

UDIN: 25229966BMJKSA7401



Annexure 1

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Sr.	Particulars	Details	
1.	Name	Mr. Manish Kumar Jain	Mr. Jitendra Shah
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Manish Kumar Jain (DIN: 06477976) as an Additional Director / Managing Director & CEO of the Company with effect from 7 th August 2025.	Resignation of Mr. Jitendra Shah (DIN: 09377846) as Managing Director & CEO of the Company, with effect from close of business hours on 7 th August 2025 for personal reason. He has mentioned in his resignation letter that there are no other reasons for his resignation.
2	Date of appointment/ re-appointment /cessation (as applicable)	with effect from 7 th August 2025.	with effect from close of business hours on 7 th August 2025.
3	Term of appointment/re-appointment	Appointed as an Additional Director of the Company w.e.f. 7 th August 2025 and also appointed as Managing Director & CEO for a period of five years with effect from 7 th August 2025 till 6 th August 2028, who is liable to retire by rotation, subject to approval of the shareholders.	Not Applicable
4	Brief profile (in case of appointment)	<p>He is Chartered Accountant having more than 25 years of experience in the field of Strategic Planning, Finance and Business Development.</p> <p>He is not debarred from holding the office of Director by virtue of any SEBI order or order by any other competent authority.</p>	Not Applicable
5	Disclosure of relationships between directors (in case of appointment of a director).	None	Not Applicable

Jitendra Rameshchandra Shah

B-104, Cosmos, Gundechas Valley of Flowers, Thakur Village, Kandivali East, Mumbai 400101

Date: 25th July, 2025

To,

The Board of Directors of
Krebs Biochemicals and Industries Limited
Kothapalli village Kasimkota Mandal, Anakapalli Dist.
Andhra Pradesh 531031

Sub: Resignation as Director/Managing Director/ CEO of the Company

I wish to resign as Managing Director / CEO as well as Director of Krebs Biochemicals and Industries Limited ("the Company") due to personal reasons. There are no any other reasons for my resignation.

Please accept my resignation at forthcoming board meeting scheduled to be held on 7th August, 2025, to be effective after the close of the business hours on the Board Meeting date.

I wish to place on record my sincere thanks to each Board Member for their support and showing confidence in me during my tenure as Managing Director / CEO/ Director of the Company.

Yours Sincerely,



Jitendra Rameshchandra Shah
DIN: 09377846